

Attorney Docket No.: 011823-002660US

PATENT

1642
IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Queen et al.

Application No.: 09/718,998

Filed: November 22, 2000

For: IMPROVED HUMANIZED
IMMUNOGLOBULINS

Examiner: Anne L. Holleran

Art Unit: 1642

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

10/25/2004 CNGUYEN 00000023 201430 09718998

01 FC:1806 180.00 DA

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance. Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Joe Liebeschuetz
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
JOL:crf

GIPE JC116
OCT 22 2004
PATENT & TRADEMARK OFFICE

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/718,998
Filing Date	November 22, 2000
First Named Inventor	Queen
Group Art Unit	1642
Examiner Name	Holleran, A. L.
Attorney Docket Number	011823-002660US

Total Number of Pages in This Submission

7

ENCLOSURES (check all that apply)

- | | | |
|--|---|---|
| <input checked="" type="checkbox"/> Fee Transmittal Form

<input type="checkbox"/> Fee Attached

<input type="checkbox"/> Amendment / Reply

<input type="checkbox"/> After Final

<input type="checkbox"/> Affidavits/declaration(s)

<input type="checkbox"/> Extension of Time Request

<input type="checkbox"/> Express Abandonment Request

<input checked="" type="checkbox"/> Information Disclosure Statement

<input type="checkbox"/> Certified Copy of Priority Document(s)

<input type="checkbox"/> Response to Missing Parts/ Incomplete Application

<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Assignment Papers (for an Application)

<input type="checkbox"/> Drawing(s)

<input type="checkbox"/> Licensing-related Papers

<input type="checkbox"/> Petition

<input type="checkbox"/> Petition to Convert to a Provisional Application

<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address

<input type="checkbox"/> Terminal Disclaimer

<input type="checkbox"/> Request for Refund

<input type="checkbox"/> CD, Number of CD(s) | <input type="checkbox"/> After Allowance Communication to Group

<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences

<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)

<input type="checkbox"/> Proprietary Information

<input type="checkbox"/> Status Letter

<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):

1) Return receipt postcard
2) Forty-three (43) references |
|--|---|---|

Remarks

The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm and Individual name

Townsend and Townsend and Crew LLP

Joe Liebeschuetz

Reg. No. 37,505

Signature

J. Liebeschuetz

Date

October 1, 2004

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date:

October 20, 2004

Typed or printed name

Christopher R. Fitting

Signature

CR Fitting

Date

October 20, 2004

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60322130 v1



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/718,998
				Filing Date	November 22, 2000
				First Named Inventor	Queen
				Art Unit	1642
				Examiner Name	Anne L. Holleran
Sheet	1	of	3	Attorney Docket Number	011823-002660US

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	AA	US-6,544,504	04-08-2003	Grint et al.	
	AB	US-2003/0044410	03-06-2003	Skurkovich et al.	
	AC	US-2003/0012790	01-16-2003	Ashkenazi et al.	
	AD	US-2003/0012787	01-06-2003	Ashkenazi et al.	
	AE	US-2002/0025316	02-28-2002	Ferguson	
	AF	US-6,350,860	02-26-2002	Buyse et al.	
	AG	US-6,333,032	12-25-2001	Skurkovich et al.	
	AH	US-6,329,511	12-11-2001	Vasquez et al.	
	AI	US-6,036,956	03-14-2000	Jacob et al.	
	AJ	US-5,951,973	09-14-1999	Lee et al.	
	AK	US-5,830,454	11-03-1998	Renauld et al.	
	AL	US-5,780,027	07-14-1998	Maroun	
	AM	US-5,674,494	10-07-1997	Strom	
	AN	US-5,665,774	09-09-1997	Armistead	
	AO	US-5,578,707	11-26-1996	Menachem et al.	
	AP	US-5,554,515	09-10-1996	Kurimoto et al.	
	AQ	US-4,975,467	12-04-1990	Ku et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	AR	EP	845 007		11-07-2001			<input type="checkbox"/>
	AS	EP	695 189		11-25-1998			<input type="checkbox"/>
	AT	EP	659 766		06-28-1995			<input type="checkbox"/>
	AU	EP	485 471		08-08-1990			<input type="checkbox"/>
	AV	EP	387 095		09-12-1990			<input type="checkbox"/>
	AW	EP	304 291		08-18-1988			<input type="checkbox"/>
	AX	CA	2297692		08-14-1998			<input type="checkbox"/>
	AY	CA	2275692		07-02-1998			<input type="checkbox"/>
	AZ	WO	02/98460		06-04-2002			<input type="checkbox"/>
	BA	WO	01/51046		01-12-2001			<input type="checkbox"/>
	BB	WO	01/30300		10-27-2000			<input type="checkbox"/>
	BC	WO	00/32634		06-08-2000			<input type="checkbox"/>
	BD	WO	99/09055		02-25-1999			<input type="checkbox"/>
	BE	WO	98/41232		09-24-1998			<input type="checkbox"/>
	BF	WO	98/28001		07-02-1998			<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.
60311820 v1




INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/718,998
				Filing Date	November 22, 2000
				First Named Inventor	Queen
				Art Unit	1642
				Examiner Name	Anne L. Holleran
Sheet	2	of	3	Attorney Docket Number	011823-002660US

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	BG	WO	97/37679		10-16-1997			<input type="checkbox"/>
	BH	WO	97/07136		08-09-1996			<input type="checkbox"/>
	BI	WO	96/34096		10-31-1996			<input type="checkbox"/>
	BJ	WO	95/34324		12-21-1995			<input type="checkbox"/>
								<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.
60311820 v1




<div>Substitute for form 1449B/PTO</div> <div>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</div> <div>(use as many sheets as necessary)</div>			Complete if Known		
			Application Number	09/718,998	
			Filing Date	November 22, 2000	
			First Named Inventor	Queen	
			Art Unit	1642	
			Examiner Name	Anne L. Holleran	
Sheet	3	of	3	Attorney Docket Number	011823-002660US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BK	BILLIAU et al., "Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma," <u>J. Immunology</u> , 140(5):1506-1510 (1988).	
	BL	BOWIE et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," <u>Science</u> , 247:1306-1310 (1990).	
	BM	BURGESS et al., "Possible Dissociation of the Heparin-binding Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue," <u>J. Cell Biology</u> , 111:2129-2138 (1990).	
	BN	FROYEN, "Potential therapeutic use of antibodies directed towards HuIFN-gamma," <u>Biotherapy</u> , 10(1):49-57 (1997).	
	BO	LAZAR et al., "Transforming Growth Factor α : Mutation of Aspartic Acid 47 and Leucine 48 Results in different Biological Activities," <u>Molecular and Cellular Biology</u> , 8(3):1247-1252 (1988).	
	BP	WENDLING, "Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody," <u>J. Rheumatology</u> , 20(2):259-262 (1993).	
	BQ	WIESENBERG, "Suppression and augmentation of rat adjuvant arthritis with monoclonal anti-interferon-gamma antibody," <u>Clin. Exp. Immunol.</u> , 78(2):245-249 (1989).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
² Applicant's unique citation designation number (optional).² Applicant is to place a check mark here if English language Translation is attached.



FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27TOTAL AMOUNT OF PAYMENT (\$)
180

Complete if Known

Application Number	09/718,998
Filing Date	November 22, 2000
First Named Inventor	Queen
Examiner Name	Holleran, A. L.
Art Unit	1642
Attorney Docket No.	011823-002660US

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None☒ Deposit Account:Deposit
Account
Number

20-1430

Deposit
Account
Name

Townsend and Townsend and Crew LLP

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments☒ Charge any additional fee(s) or any underpayment of fee(s)☐ Charge fee(s) indicated below, except for the filing fee
to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1)

(\$)

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

		Extra Claims		Fee from below		Fee Paid
Total Claims	-** =		X		=	
Independent Claims	-** =		X		=	
Multiple Dependent			X		=	

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2)

(\$)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Petitions related to provisional applications	
1806	180	1806	180	Submission of Information Disclosure Stmt	180
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR § 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR § 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid SUBTOTAL (3)

(\$)180

SUBMITTED BY

Complete (if applicable)

Name (Print/Type)	Joe Liebeschuetz	Registration No. (Attorney/Agent)	37,505	Telephone	650-326-2400
Signature				Date	October 1, 2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.